White Plains, United States
Oligomerix, Inc is an emerging biotechnology company that is focused on developing disease-modifying therapeutics for neurodegenerative diseases characterized by aberrant tau protein, ranging from rare tauopathies such as progressive supranuclear palsy and frontotemporal dementia to Alzheimer’s disease. The company is headquartered at the Westchester Park Center in White Plains, New York and has lab facilities at the Ullmann Research Center for Health Sciences within the Albert Einstein College of Medicine.
With the slogan "Developing small molecule therapeutics targeting tau for rare neuro diseases and AD - clinical studies starting 2022," Oligomerix is making strides in drug development. The company is targeting oral, small molecule, tau self-association inhibitors as a potential treatment for Alzheimer’s disease and other dementias. These therapies are intended to be easy to administer, cost-effective, and are expected to significantly contribute to the current high-cost therapeutic options in the market.
Founded in 2006, the company received a substantial $2.49M grant investment on 04 October 2022, with the investment coming from the National Institute on Aging. This investment marks a significant milestone for Oligomerix as it gears up to initiate its clinical studies in 2022.
